In the last trading session, 1.3 million Neogenomics Inc (NASDAQ:NEO) shares changed hands as the company’s beta touched 1.26. With the company’s per share price at $10.88 changed hands at -$0.29 or -2.60% during last session, the market valuation stood at $1.40B. NEO’s last price was a discount, traded about -75.64% off its 52-week high of $19.11. The share price had its 52-week low at $10.69, which suggests the last value was 1.75% up since then.
Analysts gave the Neogenomics Inc (NEO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.67. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended NEO as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Neogenomics Inc’s EPS for the current quarter is expected to be -0.01.
Neogenomics Inc (NASDAQ:NEO) trade information
Instantly NEO was in red as seen at the end of in last trading. With action -12.29%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -33.98%, with the 5-day performance at -12.29% in the red. However, in the 30-day time frame, Neogenomics Inc (NASDAQ:NEO) is -26.78% down.
The consensus price target for the stock as assigned by Wall Street analysts is 18, meaning bulls need an upside of 39.56% from its current market value. According to analyst projections, NEO’s forecast low is 18 with 18 as the target high. To hit the forecast high, the stock’s price needs a -65.44% plunge from its current level, while the stock would need to soar -65.44% for it to hit the projected low.
Neogenomics Inc (NEO) estimates and forecasts
Year-over-year growth is forecast to reach 11.62% up from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of 171.58M. 12 analysts are of the opinion that Neogenomics Inc’s revenue for the current quarter will be 182.96M. The company’s revenue for the corresponding quarters a year ago was 156.24M and 164.5M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 9.82%. The estimates for the next quarter sales put growth at 11.22%.
The 2025 estimates are for Neogenomics Inc earnings to increase by 62.34%, but the outlook for the next 5-year period is at 76.68% per year.
NEO Dividends
Neogenomics Inc is expected to release its next quarterly earnings report in March.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 11.1716% or 14.12 million shares worth $195.87 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund . With 8.28 shares estimated at $90.08 million under it, the former controlled 6.45% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 3.11% of the shares, roughly 4.0 shares worth around $43.5 million.
